There is an important precedent for inhalation delivery of exogenous lipids: the administration of pulmonary surfactant to newborns and adults with acute respiratory distress syndrome. However, to my knowledge this approach has not been exploited for the delivery of lipid-associated drugs to the lung.
No takes yet. Share an insight, caveat, or question.
Frank Martin (1990) studied this question.